{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:25:05Z","timestamp":1795040705446,"version":"4.10.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","award":["PTCG-21-1818034"],"award-info":[{"award-number":["PTCG-21-1818034"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG077685"],"award-info":[{"award-number":["R01AG077685"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG077685"],"award-info":[{"award-number":["R01AG077685"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We previously documented that regulatory T cells (Tregs) immunomodulatory mechanisms are compromised in Alzheimer\u2019s disease (AD), shifting the immune system toward a pro-inflammatory response. However, Tregs are a potentially restorable therapeutic target in AD. In this study, we evaluated the safety and efficacy of two dosing frequencies of low-dose Interleukin-2 (IL-2) in expanding Tregs to modify disease progression in AD individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase 2a, randomized, double-blind, placebo-controlled study, 38 participants were assigned to receive subcutaneous IL-2 (10^6\u00a0IU\/day) for five days, administered either every 4\u00a0weeks (IL-2 q4wks) or every 2\u00a0weeks (IL-2 q2wks), versus placebo, for 21\u00a0weeks, followed by 9\u00a0weeks of observation. The primary endpoints were the incidence and severity of adverse events. For the secondary endpoints, changes in Treg numbers and suppressive functions were evaluated. Exploratory endpoints included changes in plasma inflammatory mediators, CSF AD-related biomarkers, and clinical scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 38 participants, 9 received IL-2 q4wks, 10 received IL-2 q2wks, and 19 received placebo. All participants completed the trial with no serious adverse events or deaths. Both IL-2 dosing regimens increased Treg numbers and suppressive function, but IL-2 q4wks treatment exhibited superiority in enhancing Treg percentage and Foxp3 mean fluorescent intensity. In longitudinal analysis of 45 inflammatory mediators, IL-2 q4wks administration demonstrated greater efficacy in alleviating the plasma inflammatory mediators CCL2, CCL11, and IL-15, while enhancing IL-4 and CCL13 levels. A significant improvement in CSF A\u03b242 levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045 vs. placebo) on Day 148 was observed following IL-2 q4wks administration, compared to placebo. While CSF NfL increased by 217\u00a0pg\/ml in placebo recipients, it remained stable in the IL-2 q4wks group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.060, IL-2 q4wks vs. placebo). The adjusted mean change from baseline in the ADAS-cog score at week 22 indicated a trend toward slower clinical progression in IL-2 q4wks recipients compared to placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.061).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The IL-2 immunotherapeutic strategy was safe and well-tolerated. IL-2 q4wks effectively expanded Treg populations, leading to modification in inflammatory mediators and CSF A\u03b242 levels, while also showing promising trends on clinical scales. These findings provide a foundation for further investigation of low-dose IL-2 as a potential treatment for Alzheimer\u2019s Disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT06096090, Registration Date: 10-17-2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01791-x","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:33:03Z","timestamp":1751607183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Low-dose interleukin-2 in patients with mild to moderate Alzheimer\u2019s disease: a randomized clinical trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Alireza","family":"Faridar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazaret","family":"Gamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Boradia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Thome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Beers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Thonhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad O.","family":"Nakawah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo C.","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon B.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grundman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Masdeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley H.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"issue":"3","key":"1791_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","volume":"51","author":"IE Jansen","year":"2019","unstructured":"Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat Genet. 2019;51(3):404\u201313.","journal-title":"Nat Genet"},{"issue":"4","key":"1791_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54(4):412\u201336.","journal-title":"Nat Genet"},{"issue":"7685","key":"1791_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, et al. Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer\u2019s disease. Nature. 2017;552(7685):355\u201361.","journal-title":"Nature"},{"issue":"7","key":"1791_CR4","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29(7):1775\u201381.","journal-title":"Nat Med"},{"key":"1791_CR5","doi-asserted-by":"publisher","first-page":"135279","DOI":"10.1016\/j.neulet.2020.135279","volume":"736","author":"Y Liu","year":"2020","unstructured":"Liu Y, Dai Y, Li Q, Chen C, Chen H, Song Y, et al. Beta-amyloid activates NLRP3 inflammasome via TLR4 in mouse microglia. Neurosci Lett. 2020;736:135279.","journal-title":"Neurosci Lett"},{"issue":"7784","key":"1791_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669\u201373.","journal-title":"Nature"},{"issue":"3","key":"1791_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3233\/JAD-160912","volume":"55","author":"AN Nilson","year":"2017","unstructured":"Nilson AN, English KC, Gerson JE, Barton Whittle T, Nicolas Crain C, Xue J, et al. Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases. J Alzheimers Dis. 2017;55(3):1083\u201399.","journal-title":"J Alzheimers Dis"},{"key":"1791_CR8","doi-asserted-by":"publisher","first-page":"20833","DOI":"10.1038\/srep20833","volume":"6","author":"J Di","year":"2016","unstructured":"Di J, Cohen LS, Corbo CP, Phillips GR, El Idrissi A, Alonso AD. Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss. Sci Rep. 2016;6:20833.","journal-title":"Sci Rep"},{"key":"1791_CR9","doi-asserted-by":"publisher","first-page":"122457","DOI":"10.1016\/j.lfs.2024.122457","volume":"340","author":"C Zhang","year":"2024","unstructured":"Zhang C, Qi H, Jia D, Zhao J, Xu C, Liu J, et al. Cognitive impairment in Alzheimer\u2019s disease FAD(4T) mouse model: synaptic loss facilitated by activated microglia via C1qA. Life Sci. 2024;340:122457.","journal-title":"Life Sci"},{"issue":"7806","key":"1791_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71\u20136.","journal-title":"Nature"},{"issue":"2","key":"1791_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1148\/radiol.2017164043","volume":"282","author":"HJ van de Haar","year":"2017","unstructured":"van de Haar HJ, Burgmans S, Jansen JF, van Osch MJ, van Buchem MA, Muller M, et al. Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology. 2017;282(2):615.","journal-title":"Radiology"},{"issue":"1","key":"1791_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41467-019-08352-5","volume":"10","author":"N Rosenzweig","year":"2019","unstructured":"Rosenzweig N, Dvir-Szternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P, et al. PD-1\/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat Commun. 2019;10(1):465.","journal-title":"Nat Commun"},{"issue":"7790","key":"1791_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","volume":"577","author":"D Gate","year":"2020","unstructured":"Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer\u2019s disease. Nature. 2020;577(7790):399\u2013404.","journal-title":"Nature"},{"issue":"1","key":"1791_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s40478-022-01447-z","volume":"10","author":"A Faridar","year":"2022","unstructured":"Faridar A, Vasquez M, Thome AD, Yin Z, Xuan H, Wang JH, et al. Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer\u2019s disease. Acta Neuropathol Commun. 2022;10(1):144.","journal-title":"Acta Neuropathol Commun"},{"issue":"33","key":"1791_CR15","doi-asserted-by":"publisher","first-page":"20088","DOI":"10.1073\/pnas.2006895117","volume":"117","author":"S Othy","year":"2020","unstructured":"Othy S, Jairaman A, Dynes JL, Dong TX, Tune C, Yeromin AV, et al. Regulatory T cells suppress Th17 cell Ca(2+) signaling in the spinal cord during murine autoimmune neuroinflammation. Proc Natl Acad Sci U S A. 2020;117(33):20088\u201399.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1791_CR16","doi-asserted-by":"publisher","first-page":"106628","DOI":"10.1016\/j.isci.2023.106628","volume":"26","author":"S Prasad","year":"2023","unstructured":"Prasad S, Singh A, Hu S, Sheng WS, Chauhan P, Lokensgard JR. Dysregulated brain regulatory T cells fail to control reactive gliosis following repeated antigen stimulation. iScience. 2023;26(5):106628.","journal-title":"iScience"},{"issue":"2","key":"1791_CR17","doi-asserted-by":"publisher","first-page":"fcaa112","DOI":"10.1093\/braincomms\/fcaa112","volume":"2","author":"A Faridar","year":"2020","unstructured":"Faridar A, Thome AD, Zhao W, Thonhoff JR, Beers DR, Pascual B, et al. Restoring regulatory T-cell dysfunction in Alzheimer\u2019s disease through ex vivo expansion. Brain Commun. 2020;2(2):fcaa112.","journal-title":"Brain Commun"},{"issue":"1","key":"1791_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13024-018-0293-1","volume":"13","author":"AD Thome","year":"2018","unstructured":"Thome AD, Faridar A, Beers DR, Thonhoff JR, Zhao W, Wen S, et al. Functional alterations of myeloid cells during the course of Alzheimer\u2019s disease. Mol Neurodegener. 2018;13(1):61.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"1791_CR19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41590-023-01604-z","volume":"24","author":"W Su","year":"2023","unstructured":"Su W, Saravia J, Risch I, Rankin S, Guy C, Chapman NM, et al. CXCR6 orchestrates brain CD8(+) T cell residency and limits mouse Alzheimer\u2019s disease pathology. Nat Immunol. 2023;24(10):1735\u201347.","journal-title":"Nat Immunol"},{"issue":"2","key":"1791_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3233\/JAD-170519","volume":"61","author":"A Kimura","year":"2018","unstructured":"Kimura A, Yoshikura N, Hayashi Y, Inuzuka T. Cerebrospinal fluid C-C motif chemokine ligand 2 Correlates with brain atrophy and cognitive impairment in Alzheimer\u2019s disease. J Alzheimers Dis. 2018;61(2):581\u20138.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"1791_CR21","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/glia.22892","volume":"63","author":"B Parajuli","year":"2015","unstructured":"Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia. 2015;63(12):2274\u201384.","journal-title":"Glia"},{"issue":"4","key":"1791_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0000000000000060","volume":"73","author":"M Zhu","year":"2014","unstructured":"Zhu M, Allard JS, Zhang Y, Perez E, Spangler EL, Becker KG, et al. Age-related brain expression and regulation of the chemokine CCL4\/MIP-1beta in APP\/PS1 double-transgenic mice. J Neuropathol Exp Neurol. 2014;73(4):362\u201374.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"1791_CR23","doi-asserted-by":"publisher","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462.","journal-title":"Oncoimmunology"},{"issue":"11","key":"1791_CR24","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ni.3540","volume":"17","author":"T Chinen","year":"2016","unstructured":"Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, et al. An essential role for the IL-2 receptor in T(reg) cell function. Nat Immunol. 2016;17(11):1322\u201333.","journal-title":"Nat Immunol"},{"issue":"3","key":"1791_CR25","doi-asserted-by":"publisher","first-page":"103270","DOI":"10.1016\/j.autrev.2023.103270","volume":"22","author":"H Yan","year":"2023","unstructured":"Yan H, Yan H, Liu L, Su R, Gao C, Li X, et al. Low-dose interleukin-2 treatment increases the proportion of regulatory T cells in patients with rheumatic diseases: a meta-analysis. Autoimmun Rev. 2023;22(3):103270.","journal-title":"Autoimmun Rev"},{"key":"1791_CR26","doi-asserted-by":"publisher","first-page":"648408","DOI":"10.3389\/fimmu.2021.648408","volume":"12","author":"H Grasshoff","year":"2021","unstructured":"Grasshoff H, Comduhr S, Monne LR, Muller A, Lamprecht P, Riemekasten G, et al. Low-dose IL-2 therapy in autoimmune and rheumatic diseases. Front Immunol. 2021;12:648408.","journal-title":"Front Immunol"},{"issue":"5","key":"1791_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283\u201394.","journal-title":"Nat Rev Immunol"},{"issue":"Pt 4","key":"1791_CR28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/brain\/awv408","volume":"139","author":"C Dansokho","year":"2016","unstructured":"Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139(Pt 4):1237\u201351.","journal-title":"Brain"},{"issue":"1","key":"1791_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40035-023-00387-5","volume":"12","author":"A Faridar","year":"2023","unstructured":"Faridar A, Eid AM, Thome AD, Zhao W, Beers DR, Pascual MB, et al. A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer\u2019s disease. Transl Neurodegener. 2023;12(1):54.","journal-title":"Transl Neurodegener"},{"issue":"9","key":"1791_CR30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.nrl.2022.05.005","volume":"39","author":"A Puig-Pijoan","year":"2024","unstructured":"Puig-Pijoan A, Garcia-Escobar G, Fernandez-Lebrero A, Manero-Borras RM, Sanchez-Benavides G, Navalpotro-Gomez I, et al. The CORCOBIA study: cut-off points of Alzheimer\u2019s disease CSF biomarkers in a clinical cohort. Neurologia (Engl Ed). 2024;39(9):756\u201365.","journal-title":"Neurologia (Engl Ed)"},{"issue":"4","key":"1791_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403\u201313.","journal-title":"Ann Neurol"},{"issue":"24","key":"1791_CR32","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","volume":"124","author":"F Van Gool","year":"2014","unstructured":"Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, et al. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood. 2014;124(24):3572\u20136.","journal-title":"Blood"},{"key":"1791_CR33","doi-asserted-by":"publisher","first-page":"1415106","DOI":"10.3389\/fneur.2024.1415106","volume":"15","author":"JR Thonhoff","year":"2024","unstructured":"Thonhoff JR, Beers DR, Zhao W, Faridar A, Thome A, Wen S, et al. A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis. Front Neurol. 2024;15:1415106.","journal-title":"Front Neurol"},{"issue":"16","key":"1791_CR34","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1182\/bloodadvances.2023009729","volume":"7","author":"H Wobma","year":"2023","unstructured":"Wobma H, Kapadia M, Kim HT, Alvarez-Calderon F, Baumeister SHC, Duncan C, et al. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023;7(16):4647\u201357.","journal-title":"Blood Adv"},{"key":"1791_CR35","doi-asserted-by":"crossref","unstructured":"Bensimon G, Leigh PN, Tree T, Malaspina A, Payan CA, Pham HP, et al. Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10492):1837\u201350.","DOI":"10.1016\/S0140-6736(25)00262-4"},{"issue":"4","key":"1791_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/eji.200838904","volume":"39","author":"P Hoffmann","year":"2009","unstructured":"Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol. 2009;39(4):1088\u201397.","journal-title":"Eur J Immunol"},{"issue":"14","key":"1791_CR37","doi-asserted-by":"publisher","first-page":"e2219086120","DOI":"10.1073\/pnas.2219086120","volume":"120","author":"C Lamarche","year":"2023","unstructured":"Lamarche C, Ward-Hartstonge K, Mi T, Lin DTS, Huang Q, Brown A, et al. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. Proc Natl Acad Sci U S A. 2023;120(14):e2219086120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1791_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/cei\/uxad051","volume":"213","author":"N Valentini","year":"2023","unstructured":"Valentini N, Requejo Cier CJ, Lamarche C. Regulatory T-cell dysfunction and its implication for cell therapy. Clin Exp Immunol. 2023;213(1):40\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"1791_CR39","doi-asserted-by":"publisher","first-page":"e85935","DOI":"10.1172\/jci.insight.85935","volume":"1","author":"DE Lowther","year":"2016","unstructured":"Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, van Dijk D, et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5):e85935.","journal-title":"JCI Insight"},{"issue":"5","key":"1791_CR40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/mt.2009.44","volume":"17","author":"T Kiyota","year":"2009","unstructured":"Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, et al. AAV1\/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP\/PS1 mice. Mol Ther. 2009;17(5):803\u20139.","journal-title":"Mol Ther"},{"issue":"11","key":"1791_CR41","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1007\/s00018-021-03830-w","volume":"78","author":"D Zhu","year":"2021","unstructured":"Zhu D, Montagne A, Zhao Z. Alzheimer\u2019s pathogenic mechanisms and underlying sex difference. Cell Mol Life Sci. 2021;78(11):4907\u201320.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1791_CR42","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.4110\/in.2024.24.e11","volume":"24","author":"H Lee","year":"2024","unstructured":"Lee H, Park SH, Shin EC. IL-15 in T-cell responses and immunopathogenesis. Immune Netw. 2024;24(1):e11.","journal-title":"Immune Netw"},{"key":"1791_CR43","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3389\/fimmu.2020.00997","volume":"11","author":"A Joly-Amado","year":"2020","unstructured":"Joly-Amado A, Hunter J, Quadri Z, Zamudio F, Rocha-Rangel PV, Chan D, et al. CCL2 overexpression in the brain promotes glial activation and accelerates tau pathology in a mouse model of tauopathy. Front Immunol. 2020;11:997.","journal-title":"Front Immunol"},{"issue":"10","key":"1791_CR44","doi-asserted-by":"publisher","first-page":"7964","DOI":"10.1007\/s12035-016-0269-5","volume":"54","author":"C Zhu","year":"2017","unstructured":"Zhu C, Xu B, Sun X, Zhu Q, Sui Y. Targeting CCR3 to reduce amyloid-beta production, tau hyperphosphorylation, and synaptic loss in a mouse model of Alzheimer\u2019s disease. Mol Neurobiol. 2017;54(10):7964\u201378.","journal-title":"Mol Neurobiol"},{"issue":"7362","key":"1791_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature10357","volume":"477","author":"SA Villeda","year":"2011","unstructured":"Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90\u20134.","journal-title":"Nature"},{"key":"1791_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s42003-019-0298-5","volume":"2","author":"MM Das","year":"2019","unstructured":"Das MM, Godoy M, Chen S, Moser VA, Avalos P, Roxas KM, et al. Young bone marrow transplantation preserves learning and memory in old mice. Commun Biol. 2019;2:73.","journal-title":"Commun Biol"},{"key":"1791_CR47","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.bbi.2023.11.015","volume":"115","author":"MA Di Castro","year":"2024","unstructured":"Di Castro MA, Garofalo S, Mormino A, Carbonari L, Di Pietro E, De Felice E, et al. Interleukin-15 alters hippocampal synaptic transmission and impairs episodic memory formation in mice. Brain Behav Immun. 2024;115:652\u201366.","journal-title":"Brain Behav Immun"},{"issue":"6","key":"1791_CR48","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nm.3569","volume":"20","author":"SA Villeda","year":"2014","unstructured":"Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20(6):659\u201363.","journal-title":"Nat Med"},{"key":"1791_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12703\/r\/10-71","volume":"10","author":"AD Keegan","year":"2021","unstructured":"Keegan AD, Leonard WJ, Zhu J. Recent advances in understanding the role of IL-4 signaling. Fac Rev. 2021;10:71.","journal-title":"Fac Rev"},{"issue":"9","key":"1791_CR50","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.4103\/1673-5374.255975","volume":"14","author":"RH Tang","year":"2019","unstructured":"Tang RH, Qi RQ, Liu HY. Interleukin-4 affects microglial autophagic flux. Neural Regen Res. 2019;14(9):1594\u2013602.","journal-title":"Neural Regen Res"},{"issue":"8","key":"1791_CR51","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1096\/fj.10-155317","volume":"24","author":"T Kiyota","year":"2010","unstructured":"Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer\u2019s disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J. 2010;24(8):3093\u2013102.","journal-title":"FASEB J"},{"key":"1791_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1326-7-36","volume":"7","author":"P Chakrabarty","year":"2012","unstructured":"Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener. 2012;7:36.","journal-title":"Mol Neurodegener"},{"key":"1791_CR53","doi-asserted-by":"publisher","first-page":"1176639","DOI":"10.3389\/fimmu.2023.1176639","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023;14:1176639.","journal-title":"Front Immunol"},{"key":"1791_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fneur.2018.00044","volume":"9","author":"Y Tong","year":"2018","unstructured":"Tong Y, Yang T, Wang J, Zhao T, Wang L, Kang Y, et al. Elevated plasma chemokines for eosinophils in neuromyelitis optica spectrum disorders during remission. Front Neurol. 2018;9:44.","journal-title":"Front Neurol"},{"issue":"18","key":"1791_CR55","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.7150\/thno.75965","volume":"12","author":"H Yang","year":"2022","unstructured":"Yang H, Park SY, Baek H, Lee C, Chung G, Liu X, et al. Adoptive therapy with amyloid-beta specific regulatory T cells alleviates Alzheimer\u2019s disease. Theranostics. 2022;12(18):7668\u201380.","journal-title":"Theranostics"},{"issue":"4","key":"1791_CR56","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s11481-023-10090-x","volume":"18","author":"L Yuan","year":"2023","unstructured":"Yuan L, Xie L, Zhang H, Zhang Y, Wei Y, Feng J, et al. Low-dose IL-2 treatment rescues cognitive deficits by repairing the imbalance between treg and Th17 cells at the middle Alzheimer\u2019s disease stage. J Neuroimmune Pharmacol. 2023;18(4):674\u201389.","journal-title":"J Neuroimmune Pharmacol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01791-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:04:02Z","timestamp":1751612642000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01791-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01791-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the Houston Methodist Research Institute (HMRI) institutional review board (IRB) committee. All patients signed informed consent prior to study enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AF, ADT, JCM, JRT declares a conflict of interest as a consultant with Coya Therapeutics, Inc. SHA declares a conflict of interest as a consultant with Implicit Bioscience and scientific advisory board chair of Coya Therapeutics, Inc. DRB declares a conflict of interest as a consultant with Implicit Bioscience and Coya Therapeutics, Inc. MG is an employee of Global R&D Partners, LLC, which received consulting fees from HMRI. CD is an employee of CSD Biostatistics, Inc, which received consulting fees from HMRI. Remaining authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}